279 related articles for article (PubMed ID: 21040659)
1. [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
Husted SE; Nielsen HK
Ugeskr Laeger; 2010 Oct; 172(42):2888-91. PubMed ID: 21040659
[TBL] [Abstract][Full Text] [Related]
2. [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
Husted SE; Nielsen HK
Ugeskr Laeger; 2010 Sep; 172(37):2522-6. PubMed ID: 20836961
[TBL] [Abstract][Full Text] [Related]
3. The use of antithrombotics for acute coronary syndromes in the emergency department: considerations and impact.
Mukherjee D; Eagle KA
Prog Cardiovasc Dis; 2007; 50(3):167-80. PubMed ID: 17976502
[TBL] [Abstract][Full Text] [Related]
4. Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
Husted S; Kher A
Ann Med; 2000 Dec; 32 Suppl 1():53-9. PubMed ID: 11209983
[TBL] [Abstract][Full Text] [Related]
5. Effect of un-fractionated heparin and low molecular weight heparin on hospital mortality in patients with non ST elevation acute coronary syndrome (ACS).
Angkasuwapala K; Ratanasumawong K; Ngarmukos T; Kehasukcharoen W; Boonsom W; Kamsa-ard S
J Med Assoc Thai; 2007 Oct; 90 Suppl 1():109-14. PubMed ID: 18431893
[TBL] [Abstract][Full Text] [Related]
6. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials.
Eikelboom JW; Quinlan DJ; Mehta SR; Turpie AG; Menown IB; Yusuf S
Circulation; 2005 Dec; 112(25):3855-67. PubMed ID: 16344381
[TBL] [Abstract][Full Text] [Related]
7. Heparin versus placebo for non-ST elevation acute coronary syndromes.
Andrade-Castellanos CA; Colunga-Lozano LE; Delgado-Figueroa N; Magee K
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD003462. PubMed ID: 24972265
[TBL] [Abstract][Full Text] [Related]
8. Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis.
Kodumuri V; Adigopula S; Singh P; Swaminathan P; Arora R; Khosla S
Am J Ther; 2011 May; 18(3):180-9. PubMed ID: 20027109
[TBL] [Abstract][Full Text] [Related]
9. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes.
Magee KD; Sevcik W; Moher D; Rowe BH
Cochrane Database Syst Rev; 2003; (1):CD002132. PubMed ID: 12535430
[TBL] [Abstract][Full Text] [Related]
10. Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes.
Nicolau JC; Cohen M; Montalescot G
J Cardiovasc Pharmacol; 2009 Jun; 53(6):440-5. PubMed ID: 19365279
[TBL] [Abstract][Full Text] [Related]
11. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.
Eikelboom JW; Anand SS; Malmberg K; Weitz JI; Ginsberg JS; Yusuf S
Lancet; 2000 Jun; 355(9219):1936-42. PubMed ID: 10859038
[TBL] [Abstract][Full Text] [Related]
12. Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes.
Moser LR; Kalus JS
Ann Pharmacother; 2004 Dec; 38(12):2094-104. PubMed ID: 15536140
[TBL] [Abstract][Full Text] [Related]
13. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
Sabatine MS; Morrow DA; Montalescot G; Dellborg M; Leiva-Pons JL; Keltai M; Murphy SA; McCabe CH; Gibson CM; Cannon CP; Antman EM; Braunwald E;
Circulation; 2005 Dec; 112(25):3846-54. PubMed ID: 16291601
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular-weight heparins for the treatment of acute coronary syndromes.
Wong GC; Giugliano RP
Semin Vasc Med; 2003 Nov; 3(4):391-402. PubMed ID: 15199446
[TBL] [Abstract][Full Text] [Related]
15. The medical management of acute coronary syndromes and potential roles for new antithrombotic agents.
Pollack CV; Goldberg AD
J Emerg Med; 2008 May; 34(4):417-28. PubMed ID: 18226874
[TBL] [Abstract][Full Text] [Related]
16. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
Haas S
Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulants in coronary artery disease.
Lee LV
Cardiol Clin; 2008 Nov; 26(4):615-28. PubMed ID: 18929235
[TBL] [Abstract][Full Text] [Related]
18. Heparin versus placebo for acute coronary syndromes.
Magee KD; Campbell SG; Moher D; Rowe BH
Cochrane Database Syst Rev; 2008 Apr; (2):CD003462. PubMed ID: 18425889
[TBL] [Abstract][Full Text] [Related]
19. Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A and 11B.
Turpie AG
Can J Cardiol; 1998 Aug; 14 Suppl E():20E-23E. PubMed ID: 9779029
[TBL] [Abstract][Full Text] [Related]
20. Improved in-hospital outcomes in acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction) despite similar TIMI risk scores.
Almeda FQ; Hendel RC; Nathan S; Meyer PM; Calvin JE; Klein LW
J Invasive Cardiol; 2003 Sep; 15(9):502-6. PubMed ID: 12947210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
